Krsnaa Diagnostics misses expectations on debut; what should investors do now?
Krsnaa’s diagnoses were lost the expectations of analysts after the actions were opened at RS 1,025, 7.4 percent on the price of RS 954 issue on August 16, on the day of the list. The stock put an execution as it rose to RS 1,099.5 Intraday (15.3 percent), but still remained without expectations that had come to open the stock to open around 30 percent of premiums.
At the time of writing this report, Krsnaa’s diagnostic actions were negotiated at RS 1,007.75 at BSE, 5.63 percent.
Most analysts advised to keep the stock in the long term and buy the stock in the correction, while investors who subscribe only to obtain listings can reserve profits.
“The company has the backing of strong feelings due to its presence and network throughout the country and the business model. The company has long-term PPP contracts and, therefore, reasonable guarantee for the visibility of income and Earnings, “said Gaurav Garg, Chief Research in Global Capitalvia Investigate.
“Investors can maintain the actions assigned for medium in the short term, it would be better to buy the stock after a correction, since the premium of listed itself is significant,” he added.
Prashanth Tapse, VP Research in Mehta Equities said Krsnaa’s diagnoses give investors the opportunity to invest and maintain in a leading and fastest growing diagnostic chain in India in multiple parameters. “Krsnaa is well positioned to capitalize on health spending through public and private sectors and I think this sector will arise as a solid alternative to the demand for health,” he said.
In addition, he said with the Government’s approach through the National Health Mission and the Awareness of Public Health, the sector can see a long-term growth of 12-15 percent of CAG that responds to the needs of people in The current situation, in which Krsnaa is well located to take advantage of demand and supply. go ahead.
Therefore, based on all the reasons, he advised investors to contain a medium-term perspective.
Astha Jain, Senior Research Analyst of Hem Securities advised the gain of booking 1/4 of the celebration and keep the remaining amount of the 3 / 4th long-term amount, since it likes the unique business model and escalation of the company.
“The company with its strong brand equity has an extensive footprint in India with a robust infrastructure. With a robust income visibility, the company is well positioned to capitalize on health spending through public and private sectors,” she said .
Yash Gupta, Equity Research Associate at Angel Broking suggests that investors release gains in Krsnaa on the day from the list and said that if investors want to have an exposure in diagnosis, then the angel runner has a positive vision of technologies of Thyrocare, since they believe that Krshnaa has weak fundamentals and had assigned a neutral. Qualification to Krsnaa Diagnostics IPO.
